Method for Treating a GD2 Positive Cancer

Abstract

Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.

1 . A method of treating a GD2 positive cancer in a patient comprising administering an anti-GD2 antibody to the patient without concomitantly administering IL-2, wherein a GD2 positive cancer is treated in the patient. 
     
     
         2 . The method of  claim 1 , further comprising treating the patient one or more times with a retinoid preceding, accompanying, and/or following administering of the anti-GD2 antibody. 
     
     
         3 . The method of  claim 1 , wherein the anti-GD2 antibody is administered to the patient as a continuous infusion for one or more days and for two or more treatment cycles. 
     
     
         4 . The method of  claim 1 , wherein the anti-GD2 antibody is not a 14G2a antibody. 
     
     
         5 . The method of  claim 1 , wherein the anti-GD2 antibody is administered to the patient as a continuous infusion and the anti-GD2 antibody is not a 14G2a antibody. 
     
     
         6 . The method of  claim 1 , wherein the patient is not concomitantly treated with GM-CSF. 
     
     
         7 . The method of  claim 1 , wherein the patient is not concomitantly treated with a cytokine. 
     
     
         8 . The method of  claim 7 , wherein the patient is not treated with IL-2, and/or GM-CSF, and/or a cytokine within the same treatment cycle and/or within the same overall treatment period. 
     
     
         9 . The method of  claim 1 , wherein the GD2 positive cancer is neuroblastoma, high risk neuroblastoma, neuroblastoma stage 4, minimal residual neuroblastoma disease, relapsed neuroblastoma, and/or refractory neuroblastoma. 
     
     
         10 . The method of  claim 1 , wherein the anti-GD2 antibody is ch14.18/CHO or ch14.18/SP2/0. 
     
     
         11 . The method of  claim 1 , wherein the anti-GD2 antibody is administered in a daily dose of 10 or 25 mg/m 2 . 
     
     
         12 . The method of  claim 1 , wherein the anti-GD2 antibody is administered for 4, 10, 14, 15, or 21 consecutive days. 
     
     
         13 . The method of  claim 1 , wherein the anti-GD2 antibody is APN311 and is administered in a dose of 10 mg/m 2 /day for 10 consecutive days for 1, 2, 3, 4, 5, 6 or more treatment cycles. 
     
     
         14 . The method of  claim 1 , wherein the anti-GD2 antibody is ch14.18/SP2/0 and is administered in a dose of 25 mg/m 2 /day for 4 consecutive days for 1, 2, 3, 4, 5 or more treatment cycles. 
     
     
         15 . The method of  claim 1 , wherein the anti-GD2 antibody is administered as a continuous intravenous infusion over 24 hours per day. 
     
     
         16 . The method of  claim 1 , wherein the administration of the anti-GD2 antibody is accompanied by the administration of a reduced dose of morphine and/or one or more other analgesic.